OmniAb CEO出售股票,因为生物技术公司报告的损失比预期的要小。 OmniAb CEO sold shares as the biotech firm reported a smaller-than-expected loss.

OmniAb公司是一家专注于治疗抗体技术的生物技术公司,其首席执行官Matthew W. Foehr在2021年4月7日出售19 382股股票,每股2美元,其所有权减少0.51%。 OmniAb Inc., a biotech firm focused on therapeutic antibody technologies, saw its CEO, Matthew W. Foehr, sell 19,382 shares on April 7, 2021, at $2.00 each, reducing his ownership by 0.51%. 内线Charles S. Berkman也出售股票。 Insider Charles S. Berkman also sold shares. 该公司在最近的收入报告中报告每股净损失0.12美元,略高于预期。 The company reported a net loss of $0.12 per share in its latest earnings report, slightly better than expected. OmniAb的股票当时价值约为2.09美元,市场上限为2.5526亿美元。 OmniAb's stock, valued around $2.09 at the time, has a market cap of $255.26 million.